| HOME >> MEDICINE >> TECHNOLOGY |
144,033141,744143,525140,702A reconciliation of reported GAAP operating loss to non-GAAP operating income/(loss) excluding non-cash and other items is provided in the table that follows (in thousands, unaudited):Quarter Ended December 31, Year ended December 31, 2010200920102009GAAP operating loss
$ (10,310)$ (47,246)$(126,743)$(173,347)Stock-based compensation
8,7889,81536,02243,762Other non-cash compensation
4,1044,44219,73520,161Depreciation and amortization
14,89211,61057,33538,198Amortization of deferred revenue
(1,875)(1,250)(7,500)(4,426)Restructuring
7,3285,60416,78016,980Non-GAAP operating income/(loss)
$ 22,927$ (17,025)$
(4,371)$ (58,672)AMYLIN PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(in thousands)(unaudited)December 31,December 31,20102009AssetsCash, cash equivalents and short-term investments
$
442,663
$
7,769Restricted cash
15,000
-Accounts receivable, net
54,645
60,732Inventories, net
118,629
99,700Other current assets
45,458
78,481Property and equipment, net
811,745
780,058Other assets
43,289
39,679Total assets
$
,531,429
$
,726,419Liabilities and stockholders' equity Current liabilities
401,595
365,369Other liabilities, net of current portion
317,654
294,754Long-term debt
468,697
643,762Stockholders' equity
343,483
422,534Total liabilities and stockholders' equity
$
,531,429
$
,726,419
'/>"/>
| SOURCE Amylin Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved |